Translating pharmacogenetics and pharmacogenomics to the clinic: progress in human and veterinary medicine

Campion, D. P. and Dowell, F. J. (2019) Translating pharmacogenetics and pharmacogenomics to the clinic: progress in human and veterinary medicine. Frontiers in Veterinary Science, 6, 22. (doi:10.3389/fvets.2019.00022) (PMID:30854372) (PMCID:PMC6396708)

Campion, D. P. and Dowell, F. J. (2019) Translating pharmacogenetics and pharmacogenomics to the clinic: progress in human and veterinary medicine. Frontiers in Veterinary Science, 6, 22. (doi:10.3389/fvets.2019.00022) (PMID:30854372) (PMCID:PMC6396708)

[img]
Preview
Text
179098.pdf - Published Version
Available under License Creative Commons Attribution.

513kB

Abstract

As targeted personalized therapy becomes more widely used in human medicine, clients will expect the veterinary clinician to be able to implement an evidence-based strategy regarding both the prescribing of medicines and also recognition of the potential for adverse drug reactions (ADR) for their pet, at breed and individual level. This review aims to provide an overview of current developments and challenges in pharmacogenetics in medicine for a veterinary audience and to map these to developments in veterinary pharmacogenetics. Pharmacogenetics has been in development over the past 100 years but has been revolutionized following the publication of the human, and then veterinary species genomes. Genetic biomarkers called pharmacogenes have been identified as specific genetic loci on chromosomes which are associated with either positive or adverse drug responses. Pharmacogene variation may be classified according to the associated drug response, such as a change in (1) the pharmacokinetics; (2) the pharmacodynamics; (3) genes in the downstream pathway of the drug or (4) the effect of “off-target” genes resulting in a response that is unrelated to the intended target. There are many barriers to translation of pharmacogenetic information to the clinic, however, in human medicine, international initiatives are promising real change in the delivery of personalized medicine by 2025. We argue that for effective translation into the veterinary clinic, clinicians, international experts, and stakeholders must collaborate to ensure quality assurance and genetic test validation so that animals may also benefit from this genomics revolution.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Dowell, Dr Fiona
Authors: Campion, D. P., and Dowell, F. J.
College/School:College of Medical Veterinary and Life Sciences > School of Veterinary Medicine
Journal Name:Frontiers in Veterinary Science
Publisher:Frontiers Media
ISSN:2297-1769
ISSN (Online):2297-1769
Copyright Holders:Copyright © 2019 Campion and Dowell
First Published:First published in Frontiers in Veterinary Science 6:22
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record